Роль иммуногистохимии в диагностике рака предстательной железы

Автор: Ефремов Г.Д.

Журнал: Экспериментальная и клиническая урология @ecuro

Статья в выпуске: 1, 2011 года.

Бесплатный доступ

Рак предстательной железы, иммуногистохимия, цитокератины, рацемаза, р53, простатспецифический антиген, простатическая кислая фосфотаза, факторы роста

Короткий адрес: https://sciup.org/142188260

IDR: 142188260

Список литературы Роль иммуногистохимии в диагностике рака предстательной железы

Gutman A.B., Gutman E.B. An A phosphate occuring in the serum of patients with metastasizing carcinoma of the prostate gland//J. Clin. Invest. 1938. Vol. 17. P. 473-478.
Hameed O., Sublett J., Humphrey P.A. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues//Am J Surg Pathol. 2005. Vol. 29. № 5. P. 579-587.
Kurita T., Medina R.T., Mills A.A., Cunha G.R. Role of p63 and basal cells in the prostate//Development. 2004. Vol. 131. № 20. P. 4955-4964.
Аляев Ю.Г., Безруков Е.А., Шестиперов П.А. Молекулярная патология рака предстательной железы: диагностическая и прогностическая значимость основных маркеров//Онкоурология. 2006. № 2. C. 45-50.
Evans A.J. Alpha-methylacyl CoA race-mase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies//J. Clin. Pathol. 2003. Vol. 56. P. 892-897.
Nassar A., Amin M.B., Sexton D.G., Cohen C. Utility of alpha-methylacyl coen-zyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer//Appl Immunohistochem Mol Morphol. 2005. Vol. 13. № 3. P. 252-255.
Rubin M.A., Bismar T.A., Andren O., Mucci L., Kim R., Shen R., Ghosh D., Wei J.T., Chinnaiyan A.M., Adami H.O., Kantoff P.W., Johansson J.E. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death//Cancer Epidemiol Biomarkers Prev. 2005. Vol. 14. № 6. P. 1424-1432.
Jiang Z., Li C., Fischer A., Dresser K., Woda B.A. Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens//Am J. Clin. Pathol. 2005. Vol. 123. № 2. P. 231-236.
Epstein JI PSA and PAP asimmunohistochemical markers in prostatecancer//Urol Clin North Am.1993. Vol. 20. P. 757-770.
Genega E.M., Hutchinson B., Reuter V.E., Gaudin P.B. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma//Mod Pathol. 2000. Vol. 13. P. 1186-1191.
Nadji M., Tabei S.Z., Castro A., Chu M., Murphy G.P., Wang M.C., Morales A.R. Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms//Cancer. 1981. Vol. 48. P. 1229-1232.
Gordon IO., Tretiakova M.S., Noffsinger A.E., Hart.J., Reuter V.E., Al-Ahmadie H.A. Prostate-specific membrane antigen expression in regeneration and repair//Mod Pathol. 2008. Vol. 21. № 12. P. 1421-1427.
Wang X, Jones T.D., Zhang S., Eble J.N., Bostwick D.G, Qian J., Lopez-Beltran A., Montironi R., Harris JJ, Cheng L. Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate//Mod Pathol. 2007. Vol. 20. P. 175-182.
Франк Г.А. Морфология рака предстательной железы//Практическая онкология. 2008. Т. 9. № 2. C. 65-70.
Grignon D.J., Caplan R., Sarkar F.H., Lawton C.A., Hammond E.H., Pilepich M.V., Forman J.D., Mesic J., Fu K.K., Abrams R.A., Pajak T.F., Shipley W.U., Cox J.D. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610//J. Natl. Cancer Inst. 1997. Vol. 89. № 2. P.158-165.
Jiang T., Jiang H., Song X.S., Li X.C., Li Q.L. P53 expression and its clinical significance in prostatic carcinoma//Zhonghua Nan Ke Xue. 2005. Vol.11. № 6. P. 448-451.
Schlomm T., Iwers L., Kirstein P., Jessen B., Kollermann J., Minner S., Passow-Drolet A., Mirlacher M., Milde-Langosch K., Graefen M., Haese A., Steuber T., Simon R., Huland H., Sauter G., Erbersdobler A. Clinical significance of p 53 alterations in surgically treated prostate cancers//Mod Pathol. 2008. Vol. 21. № 11. P. 1371-1378.
Mulligan J.M., Mai K.T., Parks W, Gerridzen R.G. Proliferating cell nuclear antigen (PCNA) and MIB 1: Markers of locally advanced and biologically aggressive prostate cancer//Can. J. Urol. 1997. Vol. 4. № 3. P. 422-425.
Ojea Calvo A., Mosteiro Cervino M.J., Dominguez Freire F., Alonso Rodrigo A., Rodriguez Iglesias B., Benavente Delgado J., Barros Rodriguez J.M., Gonzalez Pineiro A. Prognostic factors of prostate cancer: usefulness of Ki-67 expression in preoperative biopsies//Arch Esp. Urol. 2004. Vol. 57. № 8. P. 805-816.
Taftachi R., Ayhan A., Ekici S., Ergen A., Ozen H. Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67//BJU Int. 2005. Vol. 95. № 4. P. 650-654.
Scholzen T., Gerdes J The Ki-67 protein: from the known and the unknown//J. Cell. Physiol. 2000. Vol. 182. № 3. P. 311-322.
Rioux-Leclercq N., Leray E., Patard J.J, Lobel B., Guille F., Jouan F., Bellaud P., Epstein J.I. The utility of Ki-67 expression in the differential diagnosis of prostatic intraepithelial neoplasia and ductal adenocarcinoma//Hum Pathol. 2005. Vol. 36. № 5. P. 531-535.
Rubio J., Ramos D., Lopez-Guerrero JA., Iborra I., Collado A., Solsona E., Almenar S., Llombart-Bosch A. Immunohistochemical expression of ki-67 antigen, cox-2 and bax/bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens//Eur. Urol. 2005. Vol. 48, № 5. P. 745-751.
Young R.H., Srigley J.R., Amin M.B.,Ulbright T.M., Cubilla A.L. Tumors of the Prostate Gland, Seminal Vesicles, Male Urethra and Penis (fascicle 28)/2000, 3rd Edition. AFIP: Washington, DC.
Kuczyk M.A., Bokemeyer C., Hartmann J., Schubach J., Walter C., Machtens S., Knuchel R., Kollmannsberger C., Jonas U., Serth J. Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer//Oncol Rep. 2001. Vol. 8, N 6. P. 1401-1407.
Revelos K., Petraki C., Gregorakis A., Scorilas A., Papanastasiou P., Tenta R., Koutsilieris M. P27(kip1) and Ki-67 (MIB1) immunohis-tochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer//In Vivo. 2005. Vol. 19. № 5. P. 911-920.
Shaffer D.R., Viale A., Ishiwata R., Leversha M., Olgac S., Manova K., Satagopan J., Scher H., Koff A. Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate//Proc Natl Acad Sci USA. 2005. Vol. 102. № 1. P. 210-215.
Maddison L.A., Sutherland B.W., Barrios R.J., Greenberg N.M. Conditional deletion of Rb causes early stage prostate cancer//Cancer Res. 2004. Vol. 64. № 17. P. 6018-6025.
Gu H., Shang P., Zhou C. Expression of CD44v6 and E-cadherin in prostate carcinoma and metastasis of prostate carcinoma//Zhonghua Nan Ke Xue. 2004. Vol. 10. № 1. P. 32-34.
Rubin M.A., Mucci N.R., Figurski J., Fecko A., Pienta K.J., Day M.L. Ecadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology//Hum Pathol. 2001. Vol. 32. № 7. P. 690-697.
Umbas R., Schalken J.A., Aalders T.W., Carter B.S., Karthaus H.F., Schaafsma H.E., Debruyne F.M., Isaacs W.B. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer//Cancer Res. 1992. Vol. 52. № 18. P. 5104-5109.
Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas/de Muga S., Hernandez S., Agell L., Salido M., Juanpere N., Lorenzo M., Lorente J.A., Serrano S., Lloreta J.//Mod Pathol. 2010. Vol. 23. № 5. P. 703-712.
Morgia G., Falsaperla M., Malaponte G., Madonia M., Indelicato M., Travali S., Mazzarino M.C. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer//Urol.Res. 2005. Vol. 33. № 1. P. 44-50.
Semaan M., Jovenin N., Birembaut P., Menard J., Staerman F. Prognostic value of stromal immunola-belling by MMP-2, MT1-MMP and TIMP-2 in clinically localized prostate cancer//Prog. Urol. 2005. Vol. 15. № 2. P. 250-254.

Еще

Статья